Loma Therapeutics ApS
CVR 44226189 · Private limited company (ApS) · Active · Low risk
Loma Therapeutics ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.9% over the next 12 months, which is 0.6 times the average for Danish companies. 2 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -8.1m and a net result of DKK -3.5m. CEO: Ditte Rahbæk Boilesen, Stephanie Holstein-Rønsbo.
Bankruptcy risk for Loma Therapeutics ApS
0.6 × the average (1.41%) · higher risk than 69% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 44226189
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (3 years)
- Address
- c/o BioInnovation Institute, Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 40k
- Auditor
- RSM Danmark, Statsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 2 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -110.7% |
| Current ratio | 1,386% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -483k | DKK -2.1m |
| Net profit | DKK -3.5m | DKK -4.6m |
| Equity | DKK -8.1m | DKK -4.6m |
| Total assets | DKK 7.3m | DKK 5.1m |
| Cash | DKK 7.2m | DKK 5.0m |
| Short-term debt | DKK 530k | DKK 334k |
| Avg. employees | 5 | 5 |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · RSM Danmark, Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 147 | ||
| 9 Aug 2023 – 31 Dec 2024 | 156 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Ditte Rahbæk Boilesen | Current | |
| CEO | Stephanie Holstein-Rønsbo | Current | |
| Board | Alejandra Maria Cristina Bonifacini Mørk | Current | |
| Board | Leif Helth Jensen | Current | |
| Board | Stuart John Myles Collinson | Current | |
| Board | Ralf Wagner | Current | |
| Owner (33%) | Ditte Boilesen Holding ApS | Current | |
| Owner (33%) | Holstein-Rønsbo Holding ApS | Current | |
| Owner (5%) | Northgaard Holding ApS | Current | |
| Auditor | Taastrup 2024 P/S | ||
| Auditor | RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | PETER HOLST CONSULTING ApS | Current | |
| Founder | Ditte Boilesen Holding ApS | Current | |
| Founder | Holstein-Rønsbo Holding ApS | Current | |
| Founder | WFLAG Holding GmbH | Current | |
| Founder | Christian Thirion | Current |
The CEOs' other companies
Ditte Rahbæk Boilesen – 1 other companies
- Ditte Boilesen Holding ApS Active
Stephanie Holstein-Rønsbo – 1 other companies
- Holstein-Rønsbo Holding ApS Active
Address history (0 moves)
| c/o BioInnovation Institute, Ole Maaløes Vej 3, 2200 København N |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Loma Therapeutics ApS
Has Loma Therapeutics ApS gone bankrupt?
No, Loma Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Loma Therapeutics ApS?
Our model estimates a bankruptcy risk of 0.9% over the next 12 months (low risk), which is 0.6 times the average for Danish companies.
Who is the CEO of Loma Therapeutics ApS?
Ditte Rahbæk Boilesen, Stephanie Holstein-Rønsbo are the CEOs of Loma Therapeutics ApS.
Who is the auditor of Loma Therapeutics ApS?
Loma Therapeutics ApS most recently used RSM Danmark, Statsautoriseret Revisionspartnerselskab.
When was Loma Therapeutics ApS founded?
Loma Therapeutics ApS was founded on 9 August 2023.
What is the equity of Loma Therapeutics ApS?
Equity was DKK -8.1m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.